Affinium Pharmaceuticals, Ltd., Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections

Affinium Pharmaceuticals, Ltd., Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections PR Newswire AUSTIN, Texas and TORONTO, August 7, 2012 AUSTIN, Texas and TORONTO, August 7, 2012 /PRNewswire/ -- Affinium Pharmaceuticals announced today that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI"). This Phase 2 trial is the first human efficacy study conducted with a new class of antibiotics designed to specifically inhibit staphylococcal fatty acid biosynthesis via a new drug target, the fatty acid synthase II (FASII) system. Results expected in late 2012 will represent a significant proof-of-concept milestone for this unique, Staphylococcus-specific antibiotic, AFN-1252. The objectives of the study are to confirm efficacy, safety and tolerability of 200 mg of oral AFN-1252 dosed twice daily for 5-14 days in patients with serious, suspected staphylococcal skin infections recruited in the outpatient or emergency room settings. The trial evaluates both the traditional endpoints at end of treatment and early endpoints currently recommended by the FDA. "We are delighted with the ease and rate of patient recruitment in our study," said Dr. Barry Hafkin, Chief Medical Officer at Affinium. Dr.